BLI:NSD-Berkeley Lights, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 48.06

Change

0.00 (0.00)%

Market Cap

USD 3.21B

Volume

0.28M

Avg Analyst Target

USD 82.67 (+72.01%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. The company was incorporated in 2011 and is headquartered in Emeryville, California.

Company Website : http://www.berkeleylights.com

Address : 5858 Horton Street, EmeryVille, CA, United States, 94608

Employees : 230

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 113.53

Short Ratio : 3.42

52 Week Low : 35.51

Shorted Shares : 3,695,260

200 Day Moving Average : 55.44

Shorted Shares Previous Month : 2,868,202

50 Day Moving Average : 47.00

Shares Held By Insiders : 17.77%

Short Percentage : 6.00%

Shares Held by Institutions : 60.17%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

N/A

 USD140.07B 233.80 177.21
BNTX BioNTech SE

N/A

 USD68.10B 51.40 36.74
REGN Regeneron Pharmaceuticals, Inc

N/A

 USD62.47B 16.69 13.10
VRTX Vertex Pharmaceuticals Incorpo..

N/A

 USD51.90B 19.11 12.98
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene, Ltd

N/A

 USD29.28B N/A N/A
GMAB Genmab A/S

N/A

 USD29.00B 33.07 3.64
SGEN Seagen Inc

N/A

 USD26.42B 40.63 36.27
RPRX Royalty Pharma plc

N/A

 USD24.49B 33.25 14.58
ALNY Alnylam Pharmaceuticals, Inc

N/A

 USD21.44B N/A N/A

ETFs Containing BLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -46.25% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.25% 11% F 5% F
Trailing 12 Months  
Capital Gain -19.23% 42% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.23% 42% F 14% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -0.25% 32% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.25% 32% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 2.19% 100% A+ 98% A+
Risk Adjusted Return -11.16% 25% F 15% F
Market Capitalization 3.21B 89% B+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 89% B+ 100% A+
Price/Book Ratio 13.32 12% F 10% F
Price / Cash Flow Ratio -89.44 95% A 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -30.46% 74% C 37% F
Return on Invested Capital -22.03% 75% C 27% F
Return on Assets -13.89% 76% C 23% F
Debt to Equity Ratio 3.39% 69% D+ 81% B-
Technical Ratios  
Short Ratio 3.42 51% F 37% F
Short Percent 9.13% 34% F 21% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector